Single dose cabergoline versus bromocriptine in inhibition of puerperal lactation: Randomised, double blind, multicentre study

Rolland, Rosalind M.; Goeij, W De; Nappi, Carmine; Colace, G.; Cabellero-Gordo, A; Falsetti, L.; Galbignani, E.; Melis, Gb; Paloetti, A; Beguin, F.; Gianoni, A; Vokaer, Alain; Mongouya, C; Thiéry, Michel; Defoort, Paul; Seiner, M; Völker, W.; Thorbert, G.

doi:10.1016/0020-7292(92)90082-t

Cited by 10 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results showed that CBG was as effective as a full treatment with bromocriptine in suppressing milk production (26). Similar data were obtained with a larger number of women (49).…”

Section: Inhibition Of Lactationsupporting

confidence: 86%

Cabergoline: A Promising Agent for the Treatment of Parkinson's Disease

Grondin

Bédard

1996

CNS Drug Reviews

View full text Add to dashboard Cite

“…The results showed that CBG was as effective as a full treatment with bromocriptine in suppressing milk production (26). Similar data were obtained with a larger number of women (49).…”

Section: Inhibition Of Lactationsupporting

confidence: 86%

Cabergoline: A Promising Agent for the Treatment of Parkinson's Disease

Grondin

Bédard

1996

CNS Drug Reviews

View full text Add to dashboard Cite

“…Bromocriptine and SKF 38393 reduced D 2 receptor densities by 85% and 35%, respectively, and D 1 receptor densities by 33% and 6%, respectively, vs. the densities in FIGURE 9 Locomotion counts by neonatal 6-OHDA-treated and sham-operated rats administered either SKF 38393 (a) (1.0, 3.0 or 10.0 mg/kg, s.c.), FCE 23884 (b) (0.1, 0.3 or 1.0 mg/kg, s.c.), or saline. Generally, cabergoline has presented a substantially greater therapeutic potency than bromocriptine for both hyperprolactemia (Ferrari et al, 1986;Rolland et al, 1991) and parkinsonian symptoms (Arai et al, 1994;Grondin et al, 1994). injection of desipramine (25 mg/kg, s.c.).…”

Section: Discussionmentioning

confidence: 99%

“…Pharmacologically, it appears that 7-OH-DPAT activates D 3 or D 2 autoreceptors, alters DA storage / release and affects postsynaptic D 2 /D 3 receptors in the limbic system as a partial agonist (e.g. The novel ergoline derivative, cabergoline, a selective DA D 2 agonist (Strolin Benedetti et al, 1990), has substantially greater therapeutic potency than bromocriptine for both hyperprolactemia (Ferrari et al, 1986;Rolland et al, 1991) and parkinsonian symptoms (Arai et al, 1994;Grondin et al, 1994;Miyagi et al, 1996a,b). The novel ergoline derivative, cabergoline, a selective DA D 2 agonist (Strolin Benedetti et al, 1990), has substantially greater therapeutic potency than bromocriptine for both hyperprolactemia (Ferrari et al, 1986;Rolland et al, 1991) and parkinsonian symptoms (Arai et al, 1994;Grondin et al, 1994;Miyagi et al, 1996a,b).…”

Section: Introductionmentioning

confidence: 99%

Effects of acute administration of DA agonists on locomotor activity: MPTP versus neonatal intracerebroventricular 6-OHDA treatment

Archer

Palomo²,

McArthur

et al. 2003

neurotox res

View full text Add to dashboard Cite

The effects of several dopamine (DA) receptor agonists upon locomotor activity on adult MPTP-treated mice and postnatal 6-hydroxydopamine- (6-OHDA-) treated rats were assessed in ten experiments. C57 BL/6 mice were administered 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 2 x 40 mg/kg, s.c., 24-hr interval between injections) at 5-months-age, while 1-day-old male Wistar rat pups were given intracisternal 6-OHDA (50 mg, once following desipramine, 25 mg/kg). MPTP-treated mice were tested 4-5 weeks following MPTP injections whereas neonatal 6-OHDA rats were tested at 3-months-age. Locomotor activity was measured in respective activity test chambers following acute administration of DA receptor agonists. In MPTP-treated mice, apomorphine failed to elevate locomotor activity but instead further exacerbated (1.0 and 3.0 mg/kg, s.c.) the hypokinesia of these animals while inducing marked increases in control mice. Cabergoline (0.3 mg/kg, s.c.) and bromocriptine (3.0 mg/kg, s.c.) caused dose-specific elevations of locomotion in MPTP and control mice but suppressed activity at the highest doses. Quinpirole (0.2 mg/kg) and 7-hydroxydipropylaminotetralin (7-OH-DPAT; 300 nmole/kg) increased locomotion in hypokinesic MPTP-treated mice; in control mice, activity was elevated by quinpirole (0.2 and 0.7 mg/kg) and 7-OH-DPAT (100 and 300 nmole/kg), while higher doses suppressed activity. Neither SKF 38393 (1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol) nor FCE 23884 [4-(9,10-didehydro-6-methylergolin-8 beta-yl) methyl-piperazine-2,6-dione] affected locomotor activity. Apomorphine (0.3, 1.0 and 2.0 mg/kg), bromocriptine (3.0 mg/kg) and cabergoline (1.0 mg/kg) stimulated locomotion in sham-operated rats, and to a greater extent in the 6-OHDA-treated rats. Higher dose cabergoline (3.0 mg/kg) induced increased activity of similar extent in sham controls and 6-OHDA treated rats. Activity-enhancing effects of quinpirole (0.2, 0.7 and 2.1 mg/kg) in sham rats were attenuated in 6-OHDA treated rats. Both SKF 38393 (10 mg/kg) and FCE 23884 (0.3 and 1.0 mg/kg) induced locomotor activity increases in 6-OHDA, but not sham, rats. Finally, 7-OH-DPAT (1200 mg/kg) enhanced activity in 6-OHDA rats vs. shams. The effects of the DA agonists are discussed with regard to the putative antihypokinesic effects in MPTP mice and DA-receptor supersensitivity effects in neonatal 6-OHDA rats, pertaining to their more-or-less selective subreceptor profiles.

show abstract

“…Cabergoline is an important advance in the treatment of hyperprolactinemia because of easier administration and, one hopes, better patient compliance (12,29,(49)(50)(51). Serum PRL is reduced up to three weeks after a single oral dose.…”

Section: Cabergolinementioning

confidence: 99%